Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
This study has been completed.
Study NCT00968825 Information provided by Revance Therapeutics, Inc.
First Received on August 27, 2009. Last Updated on June 13, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lateral Canthal Lines
Interventions listed in this trial
Botulinum Toxin Type A
Additional drug interventions recognized in this trial
Botulinum Toxins, Type A
More general drug interventions related to this trial
Central Nervous System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sponsors listed in this trial
Revance Therapeutics, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers